Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Moderna, a US-based messenger RNA (mRNA) therapeutics developer exploiting research conducted at Harvard University, raised approximately $604m in its initial public offering last Friday. The IPO, the largest ever for a biotech company, consisted of almost 26.3 million shares issued on the Nasdaq Global Select Market priced at $23.00 each, up from 21.7 million shares…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
